Delivery Order SPE2DR25D1017-SPE2DR26F9BRU
- Not listed
- The Defense Logistics Agency awarded a $1,343.05 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on August 22, 2025, with completion targeted for August 25, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded under open competition. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $1,092.72 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 9, 2025. This non-competitive delivery order was issued on September 8, 2025, and represents a firm fixed-price pharmaceutical supply transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a primary pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $4,386.42. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of December 3, 2025. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,819.08 and an ultimate completion date of December 5, 2025. This is a firm fixed price delivery order issued without any set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens with a ceiling value of $1,513.90. The contract is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and was awarded on September 26, 2025. This award carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,487.45 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of December 5, 2025. This is a firm fixed price contract with no set-aside designation, representing a competitively awarded procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order valued at $2,240.40 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This competitive award, issued on July 29, 2025, involves firm fixed price pricing with no set-aside designation. The pharmaceutical distributor will perform the contract from its corporate office location in Conshohocken, Pennsylvania, where the company is headquartered. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,177.92. The award was made on December 9, 2025, with an ultimate completion date of December 10, 2025, under a firm fixed price contract type with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, the company's headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $1,668.87 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on June 4, 2025, with an ultimate completion date of June 5, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location in the same city. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,604.51. This is a firm fixed price delivery order with an ultimate completion date of August 15, 2025, executed under a competitive procurement with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F9BRUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,762.04 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on December 17, 2025, with an ultimate completion date of December 18, 2025. The contract employs firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As the primary pharmaceutical prime vendor vehicle, this IDC enables the contractor to supply a comprehensive range of medications and medical supplies to support military healthcare programs globally, including support to the Defense Health Agency and U.S. Coast Guard. The current award for diabetes management insulin represents a routine operational requirement under this expansive pharmaceutical supply framework.